<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114153">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01705067</url>
  </required_header>
  <id_info>
    <org_study_id>2011JBCK151</org_study_id>
    <nct_id>NCT01705067</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Journey II BCS Total Knee System</brief_title>
  <acronym>NIMBLE</acronym>
  <official_title>A Retro-Prospective, Non-randomized, Consecutive Series, SIngle Cohort, Multicenter Adaptive Design Study to Evaluate the Outcomes of Total Knee Arthroplasty (TKA) Using JOURNEY™ II BCS TotaL Knee SystEm (The NIMBLE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the safety and efficacy of the JOURNEY II BCS Total Knee System in subjects with
      degenerative knee disease requiring primary total knee replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the safety and efficacy of the JOURNEY II BCS Total Knee System in subjects with
      degenerative knee disease requiring primary total knee replacement.  Pre-operative and
      operative assessments collected retrospectively.  All postoperative assessments beginning at
      the 6 month post-operative time point collected prospectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of ITB Friction Pain</measure>
    <time_frame>6 months post-operatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months post-operatively, 1 year post-operatively, 2 years post-operatively, 5 years post-operatively, and 10 years post-operatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Evaluation</measure>
    <time_frame>Baseline and 6 months post-operatively, 1 year post-operatively, 2 years post-operatively, 5 years post-operatively, and 10 years post-operatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Society Score</measure>
    <time_frame>6 months post-operatively, 1 year post-operatively, 2 years post-operatively, 5 years post-operatively, and 10 years post-operatively</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">209</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Journey II BCS TKA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects having TKA with Journey II BCS Total Knee System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TKA with Journey II BCS Total Knee System</intervention_name>
    <description>TKA with Journey II BCS Total Knee System</description>
    <arm_group_label>Journey II BCS TKA</arm_group_label>
    <other_name>Journey II BCS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject received primary total knee arthroplasty with the JOURNEY™ II BCS Total Knee
             System due to degenerative joint disease

          -  Subject is willing to sign and date an IRB approved consent form

          -  Subject is of legal age to consent

          -  Subject plans to be available through ten (10) years postoperative follow-up

          -  Subject agrees to follow the study protocol

        Exclusion Criteria:

          -  Subject received the JOURNEY™ II BCS Total Knee System on the affected knee as a
             revision for a previously failed total or unicondylar knee arthroplasty

          -  Subject received TKA on the contralateral knee as a revision for a previously failed
             total or unicondylar knee arthroplasty

          -  Subject possesses a contralateral or ipsilateral revision hip arthroplasty

          -  Subject has ipsilateral hip arthritis resulting in flexion contracture

          -  At the time of enrollment, subject has one or more of the following arthroplasties
             that are not fully healed and well-functioning, as determined by the investigator:

               -  Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing
                  arthroplasty

               -  Contralateral primary total knee or unicondylar knee arthroplasty

          -  At the time of surgery, subject had an active infection or sepsis (treated or
             untreated)

          -  At the time of surgery, subject had presence of malignant tumor, metastatic, or
             neoplastic disease

          -  At the time of surgery, subject had conditions that may interfere with the TKA
             survival or outcome (i.e., Paget's or Charcot's disease, vascular insufficiency,
             muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or
             neuromuscular disease)

          -  At the time of surgery, subject had contralateral lower extremity condition causing
             abnormal ambulation

          -  Subject is pregnant or plans to become pregnant during the study

          -  Subject has an emotional or neurological condition that would pre-empt their ability
             or willingness to participate in the study

          -  At the time of surgery, subject had a BMI&gt;40

          -  At the time of enrollment, subject has a BMI&gt;40

          -  Subject is enrolled in another investigational drug, biologic, or device study

          -  Subject is facing current or impending incarceration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharat Kusuma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minimally Invasive Orthopedics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheri Mersch, MS</last_name>
    <phone>901-399-1921</phone>
    <email>sheri.mersch@smith-nephew.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Joint Replacement Institute at St. Vincent Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gisselle Hernandez</last_name>
      <email>gissellehernandez@dochs.org</email>
    </contact>
    <investigator>
      <last_name>H. Michael Mynatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Surgery Outpatient Center - UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Orthopedics</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kary Stout, CCRC, MBA</last_name>
      <email>kstout@fwortho.com</email>
    </contact>
    <investigator>
      <last_name>Timothy van de Leur, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Sports Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46280</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-4892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>OrthoCarolina</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holden</last_name>
      <email>mholden@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Lang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Orthopaedic Research Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wellington Orthopaedics</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Minimally Invasive Orthopaedics</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Quinn</last_name>
      <phone>614-566-8897</phone>
    </contact>
    <investigator>
      <last_name>Sharat Kusuma, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Orthopaedic Clinics</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane O. Smith</last_name>
      <email>smithjo@tocdocs.com</email>
    </contact>
    <investigator>
      <last_name>Brian S Edkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harold E Cates, Jr., MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Antonio Orthopaedic Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Evergreen Orthopaedic Clinic</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Smith</last_name>
      <email>g.smith@proliancesurgeons.com</email>
    </contact>
    <investigator>
      <last_name>Robin Fuchs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>June 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis, Degenerative Knee Disease, TKA</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
